Literature DB >> 33578820

Molecular Classification and Tumor Microenvironment Characterization of Gallbladder Cancer by Comprehensive Genomic and Transcriptomic Analysis.

Nobutaka Ebata1,2, Masashi Fujita1, Shota Sasagawa1, Kazuhiro Maejima1, Yuki Okawa1,2, Yutaka Hatanaka3, Tomoko Mitsuhashi4, Ayako Oosawa-Tatsuguchi1, Hiroko Tanaka5, Satoru Miyano5, Toru Nakamura2, Satoshi Hirano2, Hidewaki Nakagawa1.   

Abstract

Gallbladder cancer (GBC), a rare but lethal disease, is often diagnosed at advanced stages. So far, molecular characterization of GBC is insufficient, and a comprehensive molecular portrait is warranted to uncover new targets and classify GBC. We performed a transcriptome analysis of both coding and non-coding RNAs from 36 GBC fresh-frozen samples. The results were integrated with those of comprehensive mutation profiling based on whole-genome or exome sequencing. The clustering analysis of RNA-seq data facilitated the classification of GBCs into two subclasses, characterized by high or low expression levels of TME (tumor microenvironment) genes. A correlation was observed between gene expression and pathological immunostaining. TME-rich tumors showed significantly poor prognosis and higher recurrence rate than TME-poor tumors. TME-rich tumors showed overexpression of genes involved in epithelial-to-mesenchymal transition (EMT) and inflammation or immune suppression, which was validated by immunostaining. One non-coding RNA, miR125B1, exhibited elevated expression in stroma-rich tumors, and miR125B1 knockout in GBC cell lines decreased its invasion ability and altered the EMT pathway. Mutation profiles revealed TP53 (47%) as the most commonly mutated gene, followed by ELF3 (13%) and ARID1A (11%). Mutations of ARID1A, ERBB3, and the genes related to the TGF-β signaling pathway were enriched in TME-rich tumors. This comprehensive analysis demonstrated that TME, EMT, and TGF-β pathway alterations are the main drivers of GBC and provides a new classification of GBCs that may be useful for therapeutic decision-making.

Entities:  

Keywords:  EMT; TGF-β signaling pathway; gallbladder cancer; tumor microenvironment

Year:  2021        PMID: 33578820      PMCID: PMC7916565          DOI: 10.3390/cancers13040733

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  43 in total

1.  Genomic spectra of biliary tract cancer.

Authors:  Hiromi Nakamura; Yasuhito Arai; Yasushi Totoki; Tomoki Shirota; Asmaa Elzawahry; Mamoru Kato; Natsuko Hama; Fumie Hosoda; Tomoko Urushidate; Shoko Ohashi; Nobuyoshi Hiraoka; Hidenori Ojima; Kazuaki Shimada; Takuji Okusaka; Tomoo Kosuge; Shinichi Miyagawa; Tatsuhiro Shibata
Journal:  Nat Genet       Date:  2015-08-10       Impact factor: 38.330

2.  An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers.

Authors:  Steven A Roberts; Michael S Lawrence; Leszek J Klimczak; Sara A Grimm; David Fargo; Petar Stojanov; Adam Kiezun; Gregory V Kryukov; Scott L Carter; Gordon Saksena; Shawn Harris; Ruchir R Shah; Michael A Resnick; Gad Getz; Dmitry A Gordenin
Journal:  Nat Genet       Date:  2013-07-14       Impact factor: 38.330

3.  MEG8 long noncoding RNA contributes to epigenetic progression of the epithelial-mesenchymal transition of lung and pancreatic cancer cells.

Authors:  Minoru Terashima; Akihiko Ishimura; Sasithorn Wanna-Udom; Takeshi Suzuki
Journal:  J Biol Chem       Date:  2018-09-27       Impact factor: 5.157

4.  Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.

Authors:  Christopher P Wardell; Masashi Fujita; Toru Yamada; Michele Simbolo; Matteo Fassan; Rosa Karlic; Paz Polak; Jaegil Kim; Yutaka Hatanaka; Kazuhiro Maejima; Rita T Lawlor; Yoshitsugu Nakanishi; Tomoko Mitsuhashi; Akihiro Fujimoto; Mayuko Furuta; Andrea Ruzzenente; Simone Conci; Ayako Oosawa; Aya Sasaki-Oku; Kaoru Nakano; Hiroko Tanaka; Yujiro Yamamoto; Kubo Michiaki; Yoshiiku Kawakami; Hiroshi Aikata; Masaki Ueno; Shinya Hayami; Kunihito Gotoh; Shun-Ichi Ariizumi; Masakazu Yamamoto; Hiroki Yamaue; Kazuaki Chayama; Satoru Miyano; Gad Getz; Aldo Scarpa; Satoshi Hirano; Toru Nakamura; Hidewaki Nakagawa
Journal:  J Hepatol       Date:  2018-01-31       Impact factor: 25.083

Review 5.  Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer.

Authors:  Claire Vennin; Kendelle J Murphy; Jennifer P Morton; Thomas R Cox; Marina Pajic; Paul Timpson
Journal:  Gastroenterology       Date:  2017-12-26       Impact factor: 22.682

6.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data.

Authors:  Kai Wang; Mingyao Li; Hakon Hakonarson
Journal:  Nucleic Acids Res       Date:  2010-07-03       Impact factor: 16.971

7.  Clinical-Grade Human Multipotent Adult Progenitor Cells Block CD8+ Cytotoxic T Lymphocytes.

Authors:  Jeroen Plessers; Emily Dekimpe; Matthias Van Woensel; Valerie D Roobrouck; Dominique M Bullens; Jef Pinxteren; Catherine M Verfaillie; Stefaan W Van Gool
Journal:  Stem Cells Transl Med       Date:  2016-07-27       Impact factor: 6.940

8.  Targeting specificity of APOBEC-based cytosine base editor in human iPSCs determined by whole genome sequencing.

Authors:  Erica McGrath; Hyunsu Shin; Linyi Zhang; Je-Nie Phue; Wells W Wu; Rong-Fong Shen; Yoon-Young Jang; Javier Revollo; Zhaohui Ye
Journal:  Nat Commun       Date:  2019-11-25       Impact factor: 14.919

9.  Fast and accurate short read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2009-05-18       Impact factor: 6.937

10.  Hsa_circ_0046264 up-regulated BRCA2 to suppress lung cancer through targeting hsa-miR-1245.

Authors:  Liu Yang; Jun Wang; Yaodong Fan; Kun Yu; Baowei Jiao; Xiaosan Su
Journal:  Respir Res       Date:  2018-06-11
View more
  4 in total

1.  Transcriptomic-Based Identification of the Immuno-Oncogenic Signature of Cholangiocarcinoma for HLC-018 Multi-Target Therapy Exploration.

Authors:  Bashir Lawal; Yu-Cheng Kuo; Sung-Ling Tang; Feng-Cheng Liu; Alexander T H Wu; Hung-Yun Lin; Hsu-Shan Huang
Journal:  Cells       Date:  2021-10-25       Impact factor: 6.600

2.  CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer.

Authors:  Lu Cao; Kim R Bridle; Ritu Shrestha; Prashanth Prithviraj; Darrell H G Crawford; Aparna Jayachandran
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

3.  HHLA2 promotes tumor progression by long non‑coding RNA H19 in human gallbladder cancer.

Authors:  Yizhou Zhang; Hanrong Li; Chao Lv; Baokang Wu; Yang Yu; Chongli Zhong; Qi Lang; Zhiyun Liang; Yang Li; Yu Shi; Jian Zhang; Feng Xu; Yu Tian
Journal:  Int J Oncol       Date:  2022-08-03       Impact factor: 5.884

Review 4.  Preoperative Assessment and Perioperative Management of Resectable Gallbladder Cancer in the Era of Precision Medicine and Novel Technologies: State of the Art and Future Perspectives.

Authors:  Gianluca Cassese; Ho-Seong Han; Yoo-Seok Yoon; Jun Suh Lee; Jai Young Cho; Hae-Won Lee; Boram Lee; Roberto Ivan Troisi
Journal:  Diagnostics (Basel)       Date:  2022-07-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.